Ibrutinib dose intensity in high-risk chronic lymphocytic leukemia

Gabriela Forestieri; Lodovico Terzi Di Bergamo; Marina Deodato; Anna Maria Frustaci; Riccardo Moia; Clara Deambrogi; Silvia Rasi; Francesco Autore; Michele Merli; Maria Clara Merli; Roberta Mattarucchi; Gaby Fahrni; Lydia Scarfo’; Daniela Gussetti; Pietro Bulian; Annagiulia Zanatta; Valeria Spina; Alessio Bruscaggin; Katia Pini; Deborah Piffaretti; Maria Cristina Pirosa; Matin Salehi; Joyce Marques De Almeida; Jakob Passweg; Franco Cavalli; Emanuele Zucca; Bernhard Gerber; Georg Stussi; Valter Gattei; Paolo Ghia; Michael Gregor; Francesco Passamonti; Luca Laurenti; Gianluca Gaidano; Alessandra Tedeschi; Davide Rossi; Dario Rossi; Adalgisa Condoluci

doi:10.1002/hon.3032

Ibrutinib dose intensity in high-risk chronic lymphocytic leukemia

Gabriela Forestieri
, Lodovico Terzi Di Bergamo
, Marina Deodato
, Anna Maria Frustaci
, Riccardo Moia
, Clara Deambrogi
, Silvia Rasi
, Francesco Autore
, Michele Merli
, Maria Clara Merli
, Roberta Mattarucchi
, Gaby Fahrni
, Lydia Scarfo’
, Daniela Gussetti
, Pietro Bulian
, Annagiulia Zanatta
, Valeria Spina
, Alessio Bruscaggin
, Katia Pini
, Deborah Piffaretti

Maria Cristina Pirosa, Matin Salehi, Joyce Marques De Almeida, Jakob Passweg, Franco Cavalli, Emanuele Zucca, Bernhard Gerber, Georg Stussi, Valter Gattei, Paolo Ghia, Michael Gregor, Francesco Passamonti, Luca Laurenti, Gianluca Gaidano, Alessandra Tedeschi, Davide Rossi, Dario Rossi, Adalgisa Condoluci

Università della Svizzera italiana
Asst Grande Ospedale Metropolitano Niguarda
University of Eastern Piedmont
University of Insubria
Kantonsspital Luzern
San Raffaele Scientific Institute
IRCCS Centro di Riferimento Oncologico - Aviano PN
University of Basel
Oncology Institute of Southern Switzerland (IOSI)

Research output: Contribution to journal › Article

Original language	English
Pages (from-to)	1100-1104
Number of pages	5
Journal	Hematological Oncology
Volume	40
DOIs	https://doi.org/10.1002/hon.3032
Publication status	Published - 2022

Keywords

chronic lymphocytic leukemia
ibrutinib
dose intensity

Access to Document

10.1002/hon.3032

Cite this

Forestieri, G., Terzi Di Bergamo, L., Deodato, M., Frustaci, A. M., Moia, R., Deambrogi, C., Rasi, S., Autore, F., Merli, M., Merli, M. C., Mattarucchi, R., Fahrni, G., Scarfo’, L., Gussetti, D., Bulian, P., Zanatta, A., Spina, V., Bruscaggin, A., Pini, K., ... Condoluci, A. (2022). Ibrutinib dose intensity in high-risk chronic lymphocytic leukemia. Hematological Oncology, 40, 1100-1104. https://doi.org/10.1002/hon.3032

@article{0167fe48c0b24e538630baf2b9c6060b,

title = "Ibrutinib dose intensity in high-risk chronic lymphocytic leukemia",

keywords = "chronic lymphocytic leukemia, ibrutinib, dose intensity, chronic lymphocytic leukemia, ibrutinib, dose intensity",

author = "Gabriela Forestieri and \{Terzi Di Bergamo\}, Lodovico and Marina Deodato and Frustaci, \{Anna Maria\} and Riccardo Moia and Clara Deambrogi and Silvia Rasi and Francesco Autore and Michele Merli and Merli, \{Maria Clara\} and Roberta Mattarucchi and Gaby Fahrni and Lydia Scarfo{\textquoteright} and Daniela Gussetti and Pietro Bulian and Annagiulia Zanatta and Valeria Spina and Alessio Bruscaggin and Katia Pini and Deborah Piffaretti and Pirosa, \{Maria Cristina\} and Matin Salehi and \{Marques De Almeida\}, Joyce and Jakob Passweg and Franco Cavalli and Emanuele Zucca and Bernhard Gerber and Georg Stussi and Valter Gattei and Paolo Ghia and Michael Gregor and Francesco Passamonti and Luca Laurenti and Gianluca Gaidano and Alessandra Tedeschi and Davide Rossi and Dario Rossi and Adalgisa Condoluci",

year = "2022",

doi = "10.1002/hon.3032",

language = "English",

volume = "40",

pages = "1100--1104",

journal = "Hematological Oncology",

issn = "0278-0232",

publisher = "John Wiley and Sons Ltd",

}

Forestieri, G, Terzi Di Bergamo, L, Deodato, M, Frustaci, AM, Moia, R, Deambrogi, C, Rasi, S, Autore, F, Merli, M, Merli, MC, Mattarucchi, R, Fahrni, G, Scarfo’, L, Gussetti, D, Bulian, P, Zanatta, A, Spina, V, Bruscaggin, A, Pini, K, Piffaretti, D, Pirosa, MC, Salehi, M, Marques De Almeida, J, Passweg, J, Cavalli, F, Zucca, E, Gerber, B, Stussi, G, Gattei, V, Ghia, P, Gregor, M, Passamonti, F, Laurenti, L, Gaidano, G, Tedeschi, A, Rossi, D, Rossi, D & Condoluci, A 2022, 'Ibrutinib dose intensity in high-risk chronic lymphocytic leukemia', Hematological Oncology, vol. 40, pp. 1100-1104. https://doi.org/10.1002/hon.3032

TY - JOUR

T1 - Ibrutinib dose intensity in high-risk chronic lymphocytic leukemia

AU - Forestieri, Gabriela

AU - Terzi Di Bergamo, Lodovico

AU - Deodato, Marina

AU - Frustaci, Anna Maria

AU - Moia, Riccardo

AU - Deambrogi, Clara

AU - Rasi, Silvia

AU - Autore, Francesco

AU - Merli, Michele

AU - Merli, Maria Clara

AU - Mattarucchi, Roberta

AU - Fahrni, Gaby

AU - Scarfo’, Lydia

AU - Gussetti, Daniela

AU - Bulian, Pietro

AU - Zanatta, Annagiulia

AU - Spina, Valeria

AU - Bruscaggin, Alessio

AU - Pini, Katia

AU - Piffaretti, Deborah

AU - Pirosa, Maria Cristina

AU - Salehi, Matin

AU - Marques De Almeida, Joyce

AU - Passweg, Jakob

AU - Cavalli, Franco

AU - Zucca, Emanuele

AU - Gerber, Bernhard

AU - Stussi, Georg

AU - Gattei, Valter

AU - Ghia, Paolo

AU - Gregor, Michael

AU - Passamonti, Francesco

AU - Laurenti, Luca

AU - Gaidano, Gianluca

AU - Tedeschi, Alessandra

AU - Rossi, Davide

AU - Rossi, Dario

AU - Condoluci, Adalgisa

PY - 2022

Y1 - 2022

KW - chronic lymphocytic leukemia

KW - ibrutinib

KW - dose intensity

KW - chronic lymphocytic leukemia

KW - ibrutinib

KW - dose intensity

UR - http://hdl.handle.net/10807/235630

U2 - 10.1002/hon.3032

DO - 10.1002/hon.3032

M3 - Article

SN - 0278-0232

VL - 40

SP - 1100

EP - 1104

JO - Hematological Oncology

JF - Hematological Oncology

ER -

Ibrutinib dose intensity in high-risk chronic lymphocytic leukemia

Keywords

Access to Document

Other files and links

Cite this